Table 1.

The results of acylcarnitine in dried blood spots and serum on day 0 and 4, and those in the sister on day 22.

	Dried blood spots (μM)				Serum (μM)
	Day 0	Day 4	(Reference)a	Sister	Day 0	Day 4	(Reference)b	Sister
C0	15.24	9.05	(10–60)	6.68	25.59	16.68	(25–100)	12.39
C2	3.02	3.09	(5–45)	7.61	3.78	3.88	(4–60)	9.61
C4	0.08	0.05	(< 1.4)	0.042	0.12	0.09	(< 1.0)	0.12
C8	0.03	0.04	(< 0.3)	0.069	0.14	0.11	(< 0.3)	0.15
C10	0.11	0.18	(< 0.25)	0.18	0.28	0.41	(< 0.3)	0.64
C12	0.35	0.78	(< 0.4)	0.6	0.40	1.37	(< 0.2)	0.91
C14	0.43	0.69	(< 0.4)	0.37	0.45	1.07	(< 0.2)	0.53
C14:1	0.17	0.18	(< 0.3)	0.15	0.29	0.29	(< 0.2)	0.24
C16	2.80	4.78	(< 3.0)	2.29	1.45	4.35	(< 0.3)	2.44
C18	1.39	1.74	(< 2.0)	1.25	0.43	1.02	(< 0.3)	0.97
C18:1	1.40	2.75	(< 2.8)	2.06	1.01	3.37	(< 0.4)	3.57
(C16 + C18:1)/C2	1.39	2.43	(< 0.5)	0.57	0.65	1.99	(< 0.36)	0.63

The samples of the elder sister were obtained on day 22 of her age.

Underlined values are abnormal values.

^aControl values for neonatal mass screening at Shimane University were used as a reference.

^bControl values for infantile cases with high risk of fatty acid oxidation disorders at Shimane University were used as a reference.